Company research
IO Biotech, Inc.
CIK 1865494Updated Sep 27, 2026
SecurityIOBTQ · OTC · equity
IOBTQ price & chart
Loading TradingView…
OTC:IOBTQ on TradingView ↗About the company
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
In the news
SEC disclosures
IO Biotech, Inc. files 8-K: Material Event ↗
Recent filings
25-NSE - filed by Nasdaq Stock Market LLC regarding IO Biotech, Inc.
SCHEDULE 13D/A - filed by Lundbeckfond Invest A/S regarding IO Biotech, Inc.
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.
SCHEDULE 13G/A - filed by HBM Healthcare Investments (Cayman) Ltd. regarding IO Biotech, Inc.
Bankruptcy or Receivership · Triggering Events That Accelerate or Increase a Direct Financial Obligation · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 1.03, 2.04, 5.02, 8.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.05, 5.02, 8.01, 9.01
SCHEDULE 13D/A - filed by Novo Holdings A/S regarding IO Biotech, Inc.
Other Events
Items 8.01, 9.01
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 67,699,000Source | 150,718,000Source | 151,805,000Source | 222,288,000Source |
| Property, Plant and Equipment, NetUSD | 638,000Source | 847,000Source | 741,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 60,031,000Source | 143,193,000Source | 142,590,000Source | 211,531,000Source |
| Assets, CurrentUSD | 64,951,000Source | 147,255,000Source | 148,219,000Source | 221,738,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,920,000Source | 4,062,000Source | 5,629,000Source | 10,207,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,725,000Source | 2,259,000Source | 2,493,000Source | — |
| Other Assets, NoncurrentUSD | 117,000Source | 89,000Source | 84,000Source | 282,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 20,684,000Source | 17,556,000Source | 12,951,000Source | 10,364,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 66,000Source | 66,000Source | 29,000Source | 29,000Source |
| Additional Paid in CapitalUSD | 413,113,000Source | 406,587,000Source | 326,705,000Source | 319,665,000Source |
| Retained Earnings (Accumulated Deficit)USD | -359,313,000Source | -263,822,000Source | -177,739,000Source | -106,281,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,851,000Source | -9,669,000Source | -10,141,000Source | -1,489,000Source |
| Stockholders' Equity Attributable to ParentUSD | 47,015,000Source | 133,162,000Source | 138,854,000Source | 211,924,000Source |
| Liabilities and EquityUSD | 67,699,000Source | 150,718,000Source | 151,805,000Source | 222,288,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,486,000Source | 15,717,000Source | 10,676,000Source | 10,305,000Source |
| Operating Lease, Liability, CurrentUSD | 717,000Source | 655,000Source | 515,000Source | — |
| Accounts Payable, CurrentUSD | 4,661,000Source | 3,878,000Source | 4,004,000Source | 3,928,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,198,000Source | 1,839,000Source | 2,275,000Source | — |
| Other Liabilities, NoncurrentUSD | — | — | — | 59,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Current MaturitiesUSD | 0Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | — | — | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -95,491,000Source | -86,083,000Source | -71,458,000Source | -67,879,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 300,000Source | 200,000Source | 100,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,526,000Source | 8,059,000Source | 7,040,000Source | 1,791,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 782,000Source | -126,000Source | 77,000Source | 3,406,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | 87,000Source | -87,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -82,347,000Source | -71,737,000Source | -59,729,000Source | -40,646,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -44,000Source | -323,000Source | -690,000Source | -153,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 44,000Source | 323,000Source | 690,000Source | 153,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | 71,860,000Source | — | 252,951,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,526,000Source | 8,059,000Source | 7,040,000Source | 1,791,000Source |
| DepreciationUSD | 253,000Source | 215,000Source | 104,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -3,589,000Source | 331,000Source | 130,000Source | 319,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -3,589,000Source | 331,000Source | 130,000Source | — |
| General and Administrative ExpenseUSD | 23,693,000Source | 23,614,000Source | 24,438,000Source | 11,082,000Source |
| Income Tax Expense (Benefit)USD | 1,443,000Source | 852,000Source | 1,273,000Source | 68,000Source |
| Net Income (Loss) Attributable to ParentUSD | -95,491,000Source | -86,083,000Source | -71,458,000Source | -67,879,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -95,491,000Source | -86,083,000Source | -71,458,000Source | -74,987,000Source |
| Nonoperating Income (Expense)USD | 1,129,000Source | 6,212,000Source | 1,239,000Source | -26,577,000Source |
| Operating ExpensesUSD | 95,177,000Source | 91,443,000Source | 71,424,000Source | 41,234,000Source |
| Operating Lease, ExpenseUSD | 800,000Source | 700,000Source | 800,000Source | 290,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 115,115,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -95,177,000Source | -91,443,000Source | -71,424,000Source | -41,234,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -94,048,000Source | -85,231,000Source | -70,185,000Source | -67,811,000Source |
| Income Tax Expense (Benefit)USD | 1,443,000Source | 852,000Source | 1,273,000Source | 68,000Source |
| Net Income (Loss) Attributable to ParentUSD | -95,491,000Source | -86,083,000Source | -71,458,000Source | -67,879,000Source |
| Earnings Per Share, BasicUSD per share | -1.45Source | -1.98Source | -2.48Source | — |
| Earnings Per Share, DilutedUSD per share | -1.45Source | -1.98Source | -2.48Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 65,880,914Source | 43,539,976Source | 28,815,267Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 65,880,914Source | 43,539,976Source | 28,815,267Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,443,000Source | 852,000Source | 1,197,000Source | 155,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -3,589,000Source | 331,000Source | 130,000Source | 319,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -3,589,000Source | 331,000Source | 130,000Source | — |
| General and Administrative ExpenseUSD | 23,693,000Source | 23,614,000Source | 24,438,000Source | 11,082,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,977,000Source | 2,365,000Source | -1,885,000Source | 206,000Source |
| Interest ExpenseUSD | — | — | 302,000Source | 361,000Source |
| Investment Income, NetUSD | 4,718,000Source | 5,881,000Source | 1,411,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -95,491,000Source | -86,083,000Source | -71,458,000Source | -74,987,000Source |
| Nonoperating Income (Expense)USD | 1,129,000Source | 6,212,000Source | 1,239,000Source | -26,577,000Source |
| Operating ExpensesUSD | 95,177,000Source | 91,443,000Source | 71,424,000Source | 41,234,000Source |
| Operating Lease, ExpenseUSD | 800,000Source | 700,000Source | 800,000Source | 290,000Source |
| Research and Development ExpenseUSD | 71,484,000Source | 67,829,000Source | 46,986,000Source | 30,152,000Source |
Filing attachments
d13704dex991.htm · 8-K · 2026-01-30
EX-99.1 2 d13704dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Provides Corporate Update • Raymond James engaged as financial advisor • Reduction in force implemented New York, NY - January 30, 2026: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in …
Read attachment ↗d26457dex991.htm · 8-K · 2026-01-21
EX-99.1 2 d26457dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Announces Exploration of Strategic Alternatives New York, NY - January 21, 2026: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, …
Read attachment ↗d59895dex991.htm · 8-K · 2025-11-18
EX-99.1 2 d59895dex991.htm EX-99.1 EX-99.1 Breaking Boundaries. Igniting Change. Nasdaq: IOBT Jefferies Healthcare Conference November 2025 Exhibit 99.1 DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business plan, clinical trials and regulatory submis…
Read attachment ↗d36523dex991.htm · 8-K · 2025-11-14
EX-99.1 2 d36523dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missed Meeting scheduled with FDA in December to align on the design of …
Read attachment ↗d940102dex991.htm · 8-K · 2025-09-29
EX-99.1 2 d940102dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Provides Update Following Pre-BLA Meeting with FDA FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma Company implementing a restructuring, reducing its workforce by approximately 50 percent ──────────────────…
Read attachment ↗d34608dex991.htm · 8-K · 2025-08-14
EX-99.1 2 d34608dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss data and next steps for a potential regulatory submiss…
Read attachment ↗